[{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"282c5598-a3f1-4e10-8b03-9fef7b6d2b9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468426","created_at":"2021-01-18T17:05:39.851Z","updated_at":"2024-07-02T16:35:11.588Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","source_id_and_acronym":"NCT03468426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 05/03/2018","start_date":" 05/03/2018","primary_txt":" Primary completion: 08/06/2024","primary_completion_date":" 08/06/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-04-03"},{"id":"e4c18b05-2e33-449c-8b23-428803a321f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03239145","created_at":"2021-01-18T16:00:23.405Z","updated_at":"2025-02-25T16:06:38.668Z","phase":"Phase 1","brief_title":"Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT03239145","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • trebananib (AMG 386)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/31/2017","start_date":" 08/31/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-20"},{"id":"4b8ceee7-908a-4445-958c-c977257ae44f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00807859","created_at":"2021-01-18T03:04:10.693Z","updated_at":"2024-07-02T16:36:00.698Z","phase":"Phase 1","brief_title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT00807859","lead_sponsor":"Amgen","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • capecitabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 03/09/2009","start_date":" 03/09/2009","primary_txt":" Primary completion: 02/27/2014","primary_completion_date":" 02/27/2014","study_txt":" Completion: 10/19/2015","study_completion_date":" 10/19/2015","last_update_posted":"2022-11-08"},{"id":"6b88056b-740c-4793-8c44-c7eb87101b2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01555268","created_at":"2021-01-18T06:35:03.601Z","updated_at":"2024-07-02T16:36:04.006Z","phase":"Phase 1","brief_title":"Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01555268","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" VEGFA • CD34","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 10/31/2011","start_date":" 10/31/2011","primary_txt":" Primary completion: 09/24/2013","primary_completion_date":" 09/24/2013","study_txt":" Completion: 08/03/2016","study_completion_date":" 08/03/2016","last_update_posted":"2022-09-13"},{"id":"8fd2786b-62b1-42fe-adb7-71fd80110fe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808480","created_at":"2021-01-18T18:49:12.518Z","updated_at":"2024-07-02T16:36:13.876Z","phase":"Phase 2","brief_title":"Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1","source_id_and_acronym":"NCT03808480","lead_sponsor":"National Cancer Center, Korea","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • L1-10 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2022-04-06"},{"id":"e0f1a0c3-fe9e-435b-955f-31f344df4f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499352","created_at":"2021-01-18T21:33:17.500Z","updated_at":"2024-07-02T16:36:20.753Z","phase":"Phase 2","brief_title":"A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer","source_id_and_acronym":"NCT04499352","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 10/19/2020","primary_completion_date":" 10/19/2020","study_txt":" Completion: 10/19/2020","study_completion_date":" 10/19/2020","last_update_posted":"2021-11-15"},{"id":"9fbad8bb-68c1-4851-a2df-5eb9ae9738a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00479817","created_at":"2021-01-18T01:42:50.375Z","updated_at":"2024-07-02T16:36:52.301Z","phase":"Phase 2","brief_title":"Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00479817","lead_sponsor":"Amgen","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 07/05/2007","start_date":" 07/05/2007","primary_txt":" Primary completion: 08/11/2009","primary_completion_date":" 08/11/2009","study_txt":" Completion: 12/09/2019","study_completion_date":" 12/09/2019","last_update_posted":"2019-12-18"},{"id":"38df0960-76c7-4187-a0c3-d963dabfc05c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01538095","created_at":"2021-01-18T06:29:49.779Z","updated_at":"2024-07-02T16:37:28.722Z","phase":"Phase 1","brief_title":"Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors","source_id_and_acronym":"NCT01538095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-10-03"}]